Navigation Links
AFB Survey Finds Drug Labeling Puts People with Vision Loss at Serious Medical Risk
Date:1/13/2009

confusion.

Even though people of all ages with different degrees of vision loss are affected by the negative consequences of inaccessible drug labeling information, there are currently no federal or state requirements for the format of information on prescription labels.

"While some assistive devices can help people with vision loss manage medications, these technologies are not widely available," said Stacy Kelly, Ed.D., Policy Research Associate, AFB. "It is our hope that as Congress takes up healthcare reform legislation this year, one of its priorities will be to ensure that prescription drug labels and instructions are accessible to people with vision loss."

For the full report, including other personal stories, visit www.afb.org/druglabelreport.

The American Foundation for the Blind (AFB) is a national nonprofit that expands possibilities for people with vision loss. AFB's priorities include broadening access to technology; elevating the quality of information and tools for the professionals who serve people with vision loss; and promoting independent and healthy living for people with vision loss by providing them and their families with relevant and timely resources. AFB is also proud to house the Helen Keller Archives and honor the more than forty years that Helen Keller worked tirelessly with AFB. For more information visit us online at www.afb.org.

AFB has embarked on the Rx Label Enable campaign to ensure that people with vision loss have ready access to the vital information available to all consumers via prescription labeling and consumer medication information, enabling them to take medications safely, effectively, and independently. AFB is reaching out to all stakeholders, including consumers experiencing vision loss, policymakers, federal regulators
'/>"/>

SOURCE American Foundation for the Blind
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Caffeine Survey Reveals Most, Least Caffeinated Cities
2. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
3. Gerson Lehrman Group Partners With AdvaMed for Survey on Medical Device Industry
4. Economic Downturn Impacting Womens Ability to Plan for Long-Term Care Costs, New Survey Finds
5. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
6. New Survey Reveals Majority of Women of Child-Bearing Age Unaware Folic Acid Should Be Consumed Before Pregnancy
7. Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says
8. First Nationwide Folic Acid Survey of Spanish-Speaking Women Finds Most Are Missing Benefits, March of Dimes Says
9. AHP Recession Survey of Nonprofit Health Care Officials Finds Almost Half Expect Reduced Giving in 2009, Leading to Cuts in Hospital Construction and Equipment Purchases
10. Guide for Using Survey Kiosks for Instant Customer Feedback Sponsored by Opinionmeter
11. New Survey Shows Fitness Goals Trump Money Woes for Most
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 1FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 2FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 3FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 4VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 1VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 3Americans Spend Billions on Alternative Medicine 53255 1Americans Spend Billions on Alternative Medicine 53255 2Americans Spend Billions on Alternative Medicine 53255 3
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5